Ting Ting Yeoh1, Phebe Si, Lita Chew. 1. Pharmacy Department, National Cancer Centre Singapore, 11 Hospital Drive, Singapore, 169610, Singapore. yeoh.ting.ting@nccs.com.sg
Abstract
PURPOSE: This project aimed to identify common drug-related problems (DRP) among elderly cancer patients, to determine the effectiveness of medication therapy management (MTM) service in resolving DRP, to determine the clinical significance of pharmacist interventions, and to determine patients' satisfaction level of MTM service. METHOD: Elderly cancer patients (age ≥65) who were at least on one chronic medication would be eligible for the MTM service. Any DRP that was detected would be recorded and steps to resolve it were taken. Pre- and post-service patient satisfaction surveys (PSS) were conducted before and after MTM. All interventions performed by MTM pharmacists were subjected to independent evaluation by a panel of three judges. RESULTS: One hundred eighteen patients received at least one session of MTM. We identified and attempted to resolve 361 DRPs, and the most common DRPs were drug interactions (117 cases, 32.4 %), adverse effects (114 cases, 31.6 %), and non-adherence (48 cases, 13.3 %). Forty-four interventions were performed by pharmacists and forty cases (91 %) were accepted by physicians. Almost two third of these interventions were deemed significant (or higher) by the judges. Seventy-two patients completed PSS. There was statistically significant improvement in patients' satisfaction level after the service was provided. CONCLUSION: MTM is an important platform in identifying and managing DRPs. Patients are generally satisfied with MTM services.
PURPOSE: This project aimed to identify common drug-related problems (DRP) among elderly cancerpatients, to determine the effectiveness of medication therapy management (MTM) service in resolving DRP, to determine the clinical significance of pharmacist interventions, and to determine patients' satisfaction level of MTM service. METHOD: Elderly cancerpatients (age ≥65) who were at least on one chronic medication would be eligible for the MTM service. Any DRP that was detected would be recorded and steps to resolve it were taken. Pre- and post-service patient satisfaction surveys (PSS) were conducted before and after MTM. All interventions performed by MTM pharmacists were subjected to independent evaluation by a panel of three judges. RESULTS: One hundred eighteen patients received at least one session of MTM. We identified and attempted to resolve 361 DRPs, and the most common DRPs were drug interactions (117 cases, 32.4 %), adverse effects (114 cases, 31.6 %), and non-adherence (48 cases, 13.3 %). Forty-four interventions were performed by pharmacists and forty cases (91 %) were accepted by physicians. Almost two third of these interventions were deemed significant (or higher) by the judges. Seventy-two patients completed PSS. There was statistically significant improvement in patients' satisfaction level after the service was provided. CONCLUSION: MTM is an important platform in identifying and managing DRPs. Patients are generally satisfied with MTM services.
Authors: Albert J ten Tije; Jaap Verweij; Michael A Carducci; Wilfried Graveland; Theresa Rogers; Tatjana Pronk; M P Verbruggen; Fitzroy Dawkins; Sharyn D Baker Journal: J Clin Oncol Date: 2005-02-20 Impact factor: 44.544
Authors: Arti Hurria; Kayo Togawa; Supriya G Mohile; Cynthia Owusu; Heidi D Klepin; Cary P Gross; Stuart M Lichtman; Ajeet Gajra; Smita Bhatia; Vani Katheria; Shira Klapper; Kurt Hansen; Rupal Ramani; Mark Lachs; F Lennie Wong; William P Tew Journal: J Clin Oncol Date: 2011-08-01 Impact factor: 44.544
Authors: S M Lichtman; M Buchholtz; J Marino; P Schulman; S L Allen; L Weiselberg; D Budman; L DeMarco; M Schuster; J Lovecchio Journal: Age Ageing Date: 1992-05 Impact factor: 10.668
Authors: Shannon J Von Muenster; Barry L Carter; Cynthia A Weber; Michael E Ernst; Jessica L Milchak; Jennifer J G Steffensmeier; Yinghui Xu Journal: Pharm World Sci Date: 2007-08-21
Authors: C H Smorenburg; A J ten Tije; J Verweij; M Bontenbal; K Mross; D M van Zomeren; C Seynaeve; A Sparreboom Journal: Eur J Cancer Date: 2003-01 Impact factor: 9.162
Authors: Justin P Turner; Kris M Jamsen; Sepehr Shakib; Nimit Singhal; Robert Prowse; J Simon Bell Journal: Support Care Cancer Date: 2015-10-09 Impact factor: 3.603
Authors: Elze Vrijkorte; Jennifer de Vries; Ron Schaafsma; Machteld Wymenga; Thijs Oude Munnink Journal: Eur J Cancer Care (Engl) Date: 2019-11-06 Impact factor: 2.520